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Abstract 
 
Background and Objectives: Widespread empiric use of antibiotics exists especially in 
developing countries. This is a concern since inappropriate use of antibiotics, including their 
extended inappropriate use, will increase resistance rates. Consequently, there is a need to 
evaluate antibiotic utilisation across healthcare sectors to improve future use. This includes 
ceftriaxone in hospitals as it is a widely used antibiotic among hospitals including those in 
Ghana. Methods: A cross-sectional study to evaluate the appropriateness of ceftriaxone 
prescribing in a leading hospital in Ghana. Ceftriaxone prescribing in the patient record cards 
was assessed using modified WHO drug utilization evaluation criteria as well as referencing 
the national standard treatment guidelines in Ghana and the ceftriaxone package insert. Results: 
251 patients were assessed. Ceftriaxone was most commonly prescribed for comorbid malaria 
with bacterial infections, urinary tract infections, sepsis and gastroenteritis. The 
appropriateness of the indication was 86.9% (n = 218). The doses most prescribed were 1 g 
(41.4%) and 2 g (39.4%). Stat dose and once daily dosage regimen constituted 51.4% and 
84.5% respectively. The most common duration of treatment was 1 (51.4%) and 2 days 
(35.1%). The overall appropriateness of prescribing was 93.0% against a pre-set threshold of 
97.9%. Conclusion: The appropriateness of ceftriaxone prescribing was high in this leading 
hospital in Ghana. However, there is room for improvement with targeted educational 
initiatives, with further research planned.  
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INTRODUCTION 
 
Irrational antimicrobial use is a global health problem especially in developing countries. It 
often results in failure to eradicate infectious microbes, emergence of antimicrobial resistance, 
as well as unnecessary health care cost to patients and healthcare systems [1-3]. Infections are 
also becoming increasingly difficult to treat with standard first-line antibiotics due to rising 
antimicrobial resistance (AMR) rates. This is resulting in the use of newer, more targeted, but 
also more expensive antibiotics across health care sectors [1,4]. Consequently, the evaluation 
of current antibiotic use is an essential measure for assessing and improving the appropriate 
use of antibiotics across sectors in order to develop pertinent future strategies to reduce AMR 
in the future [4-8]. 
 
Since the introduction of the rational drug use concept in the mid-¶V, several efforts have 
been made to improve prescribing practices in hospitals and other settings through promoting 
drug utilization studies, reviews or evaluation initiatives [9-13]. Drug utilization research is 
generally classified into descriptive (drug use patterns or trends) and analytical (drug use 
evaluation or review) studies. Drug use evaluation (DUE) is defined by the American Society 
of Health System Pharmacists (ASHP) as a criteria-based, ongoing and systemic process for 
monitoring and evaluating the prophylactic, therapeutic and empiric use of drugs (at the 
individual patient level) to ensure medicines are provided appropriately and used effectively 
[14,15]. According to the World Health Organization [16], this aspect is drug or disease 
specific or both, and can be structured to assess the prescribing, dispensing and administering 
of medications by indications, dose, and potential drug interaction among others.  DUE can 
also be used to assess prescribing against agreed guidance, including both new and existing 
medicines [17-20]. 
 
Third-generation cephalosporins are used in the treatment of a number of infections due to their 
broad spectrum activity against most Gram-positive and Gram-negative bacteria. Ceftriaxone 
is the most prescribed antibiotic among the third generation cephalosporins and is often 
misused or overused [21-23]. In most developing countries such as Ghana, there is widespread 
empiric use of ceftriaxone among hospitalized patients as well as out-patients. This is because 
in most cases, culture and/or ceftriaxone antibiogram tests are unavailable.  
 
Consequently, the rational use of ceftriaxone is of concern to prescribers and to health care 
systems, especially with the rising AMR rates in Ghana [24].  However, we are unaware of 
any study that has been published to assess the appropriateness of prescribing of ceftriaxone 
in hospitals in Ghana. This is important as ceftriaxone is on the national health insurance drug 
list, increasing the likelihood of this antibiotic being prescribed. Other antibiotics on the 
Ghana Police hospital formulary include amoxicillin, amoxicillin/clavulanic acid, 
cefuroxime, ciprofloxacin, doxycycline, flucloxacillin, gentamicin, and metronidazole. 
 
We are aware that studies regarding antibiotic prescribing have been conducted in ambulatory 
care in Ghana, including self-medication, and there are also published studies monitoring 
antibiotic use and resistance patterns in Ghana [25-31]. We are also aware that the evaluation 
of the use of cephalosporins such as ceftriaxone is well documented in other countries, and 
has contributed to their prudent use and containing costs [5, 32-34].  
 
The Standard Treatment Guidelines (STGs) of Ghana are published by the Ministry of Health 
to guide prescribers, pharmacists, dispensers and other healthcare staff who prescribe at 
primary healthcare facilities on the care of patients with common diseases, in line with the 
essential drug concept [35]. The STGs are primarily directed at physicians working in primary 
healthcare; however, they are also used in secondary and tertiary centres.  
 
The use of the STGs to enhance the appropriate use of medicines is achieved through initiatives 
of the Ghana National Drugs Program. These include seminars for prescribers, advertisements 
in health magazines and supply of copies of the STGs to all health care facilities. The Police 
hospital, being a secondary level quasi-government health facility, has adopted the STGs and 
encourages prescribers to adhere to the guidelines through its clinical education unit where 
applicable.  Drug package inserts are also used in other secondary and tertiary hospitals in 
Ghana to guide prescribing alongside the STGs where pertinent STGs do not exist.  However, 
many health facilities in developing countries such as Ghana do not have active antibiotic 
stewardship programmes. These are considerations for the future. We are also aware that a 
number of studies have shown low adherence levels to STGs [36,37].  
 
Consequently, the aim of this study was to evaluate the current use of ceftriaxone within a 
national Police referral hospital in Ghana against published guidance. The findings will act as 
a basis for suggesting future initiatives to further promote its rational use in Ghana if applicable 
along with general moves to enhance antibiotic stewardship. 
 
METHODS 
 
Study site 
The study was conducted at the Ghana Police Hospital, Greater Accra, Ghana. The Greater 
5HJLRQLVWKHVPDOOHVWDUHDRI*KDQD¶VDGPLQLVWUDWLYHUHJLRQRFFXS\ing a total land surface 
area of 3,245 km2 , representing 1.4% of the total area of Ghana. The population of the region 
stood at just over 4 million people in 2012. There is one tertiary level referral health facility in 
Accra, one regional hospital, two quasi-government secondary level security hospitals, and a 
few private hospitals with limited in-service facilities. The Ghana Police hospital is a 100-bed 
facility providing health services to police personnel, their dependents, and the general public. 
Some of the specialist services in addition to outpatient services include gynaecological, 
surgical, paediatric, family medicine, dental, public health, ophthalmological and ear-nose-
throat services among others. The out-patient department provides services to over 100,000 
patients each year, representing an estimated 2.5% of the total population of the Greater Accra 
region. The hospital is currently undergoing expansion to cope with increasing service 
demands. It also serves as a major medical referral centre during national disasters. 
Consequently, the results of the study can provide a basis for assessing current ceftriaxone use 
within hospitals in Ghana in order to develop future strategies to improve the use of ceftriaxone 
in this and other hospitals in Ghana if pertinent. 
 
Study design 
This was a cross-sectional study conducted from January to June 2015. This study evaluated 
ceftriaxone injection use with the aid of the Pharmacy DHSDUWPHQW¶V GUXJ HYDOXDWLRQ GDWD
collection format. This included pre-set criteria for assessing ceftriaxone use based on the 
National STGs [35], and ceftriaxone injection package insert from Roche Laboratories [Batch 
number: B0008B02F93].  
  
Data collection and determination of thresholds of key variables. 
Patient cards with prescribed ceftriaxone injections from both out- and in-patient presented at 
the Pharmacy Department of the Ghana Police Hospital were assessed on receipt with the aid 
RIWKH3KDUPDF\XQLW¶VGUXJHYDOXDWLRQIRUP'HPRJUDSKLFLQIRUPDWLRQGLDJQRVLVGUXJGRVH
drug frequency, duration of treatment supportive/additional antibiotics, possible drug 
interactions and disease contraindications were obtained from the patient cards. 
A modified version of the World Health Organization (WHO) criteria was adopted for the drug 
use evaluation [38]. In line with WHO criteria for assessing medicine in the absence of hospital 
specific 67*¶s, we based our criteria on recommendations from the national STGs, which is 
principally aimed at primary care, LQ DGGLWLRQ WR PDQXIDFWXUHU¶V SDFNDJH LQVHUW. These two 
sources are seen as relevant literature sources for prescribers guidance in this setting. Hence, 
prescribing of ceftriaxone was considered appropriate if this was in line with the 
recommendations in the STGs and the manuIDFWXUHU¶Vpackage insert.  
 
Furthermore, the actual thresholds of prescribed ceftriaxone with respect to diagnosis, dose, 
frequency, duration, need for supportive/additional antibiotics, possible drug interactions and 
contraindications were determined and assessed against pre-set criteria thresholds ranging 
between 95-100%. This threshold was based on the WHO and Management Sciences for 
Health guidelines for the evaluation of drug use in hospitals [39]. Patient cards not bearing any 
of the required data on sex, age, drug dose, drug frequency, duration of treatment and diagnosis, 
were excluded. 
 
% Actual Threshold = Total observed appropriateness of each variable x 100.  
                           Total expected appropriateness of each variable  
 
There was no attempt to assess the accuracy of the diagnosis stated on the patient cards as this 
was a drug use evaluation study based on the actual data included in the record cards and did 
not involve interviews with physicians or other professionals. Some of these anyway may have 
left the hospital to practice elsewhere by the time the data was analysed. 
 
Statistical analysis 
Data generated from patient cards were categorized and analyzed with the aid of Excel 
spreadsheet (Microsoft Excel 2010), after verification and cleaning. Descriptive statistics 
(percentages, frequency and histograms) was used to analyze the data. 
 
Ethical consideration 
The study protocol received approval from the Ghana Police Hospital Administration. Patients¶ 
data were handled with utmost confidentiality, and all patients and doctors identifiers were 
removed. 
 
RESULTS 
 
Demography of patients 
Out of the 276 patients whose cards were reviewed within the study period which had 
ceftriaxone injection prescribed, 251 (90%) had all the relevant information required for 
inclusion in the evaluation of ceftriaxone use. In- and out-patients who were prescribed 
ceftriaxone injection constituted 12.4 % (31) and 87.6 % (220) of patients respectively. The 
DJHFDWHJRU\ZLWKWKHKLJKHVWSUHVFULSWLRQRIFHIWULD[RQHZDVí< 40 years (n = 95, 37.8%) 
whilst the age category with the least ceftriaxone prescriptions (n = 22, 8.8%) were patients 
older than 60 years. The gender and age categories of patients whose cards had ceftriaxone 
injection prescribed are shown in Table 1.  
 
Table 1: Gender and age characteristics of study patients prescribed ceftriaxone           (n 
= 251) 
 
Characteristics  
Frequency 
 
Percentage (%) Gender 
Male 133 53.0 
Female 118 47.0 
Age Category   
4 months to < 5 years 32 12.8 
>5 years to < 13 years 37 14.7 
>13 years to < 20 years 22 8.8 
>20 years to < 40 years 95 37.8 
>40 years to < 60 years 41 16.3 
> 61 years 24 9.6 
 
Common indications for which ceftriaxone was prescribed 
Patients diagnosed as having malaria with other bacterial infections (19.9%), urinary tract 
infections (11.6%), sepsis (9.6%) gastroenteritis (8.6%), upper respiratory tract infection 
(5.6%), appendicitis (4.8%), gastritis (3.2%), food poisoning (2.4%), fracture (2.4%), cellulitis 
(2.4%) and enteric fever (2.4%) were  the prevalent clinical conditions for which ceftriaxone 
was mostly prescribed. These top eleven indications for which ceftriaxone was prescribed 
constituted 72.9 % (183) of the cases.  Other conditions for which ceftriaxone was prescribed 
(n < 6 per diagnosis, 2.4%) constituted 27.1 % (n= 68). These included gonorrhoea, uterine 
fibroid, prostate infections, tonsillitis, appendisectomy, leukopenia, urethral discharge, herpes 
zoster, Stevens--RKQVRQ¶VV\QGURPHDQGEUeast cancer.  
 
Appropriateness of the indication  
The overall appropriateness of indications for which ceftriaxone was prescribed based on our 
methodology was 86.9% (n=218), whilst 13.1 % (n=33) were inappropriate (Table 2).  
 
Most of the malaria cases were diagnosed as co-morbid 78.0% (n=39) with bacterial infections 
such as gastroenteritis, urinary tract infections, bacterial suspected food poisoning, sepsis, 
meningitis, gonorrhoea and typhoid. The remaining malaria cases with suspected bacterial 
LQIHFWLRQV EXW QRW VWDWHG RQ WKH SDWLHQWV¶ FDUGV FRQVWLWXWHG 22.0% (n=11). Consequently, 
indications for prescribing in these cases were regarded as inappropriate. In the remaining 
frequent cases for which ceftriaxone was prescribed, it was observed that the prescriptions were 
appropriate (100%).  
 
Furthermore, in the least diagnosed cases in this study (n < 6 per diagnosis) which together 
constituted 27.1% of prescriptions, the indications  for which prescriptions for ceftriaxone was 
appropriate constituted 46 (67.7%), whilst 22 (32.3%) were inappropriate e.g. diabetes, 
hypertension, stroke and herpes zoster. The detailed results of the appropriateness of prescribed 
ceftriaxone injections are presented in Table 2.  
 
  
Table 2: Appropriateness of indications for ceftriaxone injection prescribing (n=251). 
Diagnosis Total 
number 
Number 
appropriate 
Percentage 
(%) 
appropriate 
Percentage 
(%) 
inappropriate 
Co-morbidity 
(Malaria + other 
bacterial infections) 
50 39 78.0% 22.0 % 
Urinary tract 
infection 
29 29 100% - 
Sepsis 24 24 100% - 
Gastroenteritis 22 22 100% - 
Upper respiratory 
tract infection 
14 14 100% - 
Appendicitis 12 12 100% - 
Gastritis 8 8 100% - 
Food poisoning 6 8 100% - 
Fracture (Bone 
infection) 
6 6 100% - 
Cellulitis 6 6 100% - 
Enteric fever 6 6 100% - 
Others 68 46 67.7% 32.3 % 
Total 251 218 86.9% 13.1% 
 
Pattern of prescribed ceftriaxone doses 
With respect to prescribed doses of ceftriaxone observed in this study, 1 g (41.4%) and 2 g 
(39.4%) were found to be the most prescribed doses of ceftriaxone, followed by 500 mg (9.2%) 
and (5.6%) respectively. The least prescribed doses were 125 mg, 3g and 4 g, which together 
constituted 4.4% of the doses prescribed.  
 
Daily frequency and duration of prescribed ceftriaxone. 
With respect to the daily dosage regimen, ceftriaxone stat doses (administered once) constituted 
51.4% (129 prescriptions) whilst once daily regimens which were prescribed (as stat only or 
stat and once daily) constituted 84.5% (212 prescriptions). Twice daily dosage regimens in 
equally divided doses every 12 hours constituted 10.3% (26 prescriptions), and other doses 
which given as twice daily or start then twice daily were 5.2% (13).  Ceftriaxone prescribed for 
1 day constituted 51.4% (129), whilst prescriptions for two days was 35.1% (88) and three to 
five days was 13.5% (34).  
 
Actual threshold and pre-set criteria threshold 
The study revealed that the actual threshold of prescribed ceftriaxone injections was 86.9% 
with respect to the appropriateness of the indication (diagnosis) versus the pre-set threshold of 
95%. Actual thresholds for all the doses and daily dosage regimen were appropriate (100%). 
The actual threshold for duration of prescribed ceftriaxone was 85.7% against the pre-set 
threshold of 95%. The actual threshold for prescribed supportive or additional antibiotics in 
this study was 90.3% against a pre-set threshold of 100%. The threshold obtained for the 
absence of possible drug-drug interactions was 87.7% against a pre-set threshold of 95%. There 
was no disease condition for which prescribed ceftriaxone was contraindicated, hence a 
threshold of 100%. The detailed comparison of actual and pre-set criteria thresholds is shown 
in Table 3. 
 
Table 3: Criteria threshold for ceftriaxone injection use at the Ghana Police Hospital 
Criteria assessed 
variables 
Number of cases 
assessed 
% Pre-set 
Threshold 
% Actual 
Threshold 
Indication 251 239 (95%) (218) 86.9% 
  Dose (based on age) 251 251 (100%) (251) 100% 
Daily dose regimen 251 251 (100%) (251) 100% 
Duration (based on 
severity of condition) 
251 239 (95%) (215) 85.7% 
Supportive/additional  
antibiotic required 
186 186 (100%) 168 (90.3%) 
 
Possible drug-drug 
Interaction (absence) 
251 239 (95%) (220) 87.7% 
Contraindicated Disease 
(absence) 
251 251 (100%) (251) 100% 
Overall appropriateness 1692 1656/1692 (97.9%) 1574/1692 (93.0%) 
*NB. The criteria for assessing variables was as specified in STGs and ceftriaxone 
package insert. 
 
DISCUSSION 
 
Drug use HYDOXDWLRQLQYROYHVDWKRURXJKUHYLHZRISDWLHQWV¶SUHVFULSWLRQDQGPHGLFDWLRQGDWD
before, during and after dispensing in order to assure appropriate therapeutic decision-making 
and positive outcomes [40]. According to the WHO [38], the credibility and acceptance of drug 
use evaluation depends on using criteria developed from established evidenced based 
medicines from reputable sources. Furthermore, the criteria for use of any medicine must be 
established using health facilities STGs. Other sources for developing criteria in the absence 
hospital STGs are recommendations from national, locally available satisfactory drug use 
protocols, other relevant literature sources and/or recognised international or local experts.  
 
In this study, malaria with suspected bacterial infections such as upper respiratory tract 
infections (URTIs), typhoid, sepsis, gastroenteritis and gonorrhoea among others, constituted 
19.9 % of the indications for which ceftriaxone was prescribed in hospitals in Ghana. However, 
we could not determine whether the diagnosis of malaria with suspected bacterial infections 
was always supported by the results of rapid diagnostic tests and laboratory culture results as 
this was not always recorded. This will be an area of focus in the future.  
 
Comorbid and non-comorbid diagnosis in a similar ceftriaxone evaluation study in Nepal was 
found to constitute 27.8% and 72.2% respectively [41].  Indications such as URTI-pneumonia 
(20.9%) and sepsis (20.9%) were higher than our study, though the frequency of UTIs (9.8%) 
and typhoid fever (2.7%) were comparable [42]. This though may be down to casemix 
differences between the two populations. 
 
Overall, the appropriateness of indications for which ceftriaxone injection was prescribed was 
86.9% in this study (Table 3), and may be because we included the package insert to help 
determine appropriateness, and there have been educational activities to enhance appropriate 
prescribing of ceftriaxone. 
 
The appropriateness of prescribed ceftriaxone with respect to indication, dose, frequency, 
duration, supportive/complementary antibiotic therapy, possible drug-drug interactions and 
contraindications was also high at 93%. This appreciably higher than 48.9% and 44.6% 
obtained from a similar study in public and private hospitals in Ethiopia [48]. This was despite 
our study including three additional variables in the determination of overall appropriateness 
of ceftriaxone prescribed. However, Shimels et al used their national STGs as their reference 
point. Other studies have also documented lower rates of appropriateness of prescribed 
ceftriaxone, for example, 38 % in a tertiary hospital at Port Spain, Trinidad [44] and 35.8% at 
Ayder Referral Hospital, Ethiopia [42]. Abebe et al based their appropriateness of ceftriaxone 
use on the indication, dose, frequency and duration against the Ethiopian STGs only.  
 
Higher levels of the appropriateness of prescribed ceftriaxone have though been seen in other 
studies, e.g. 73.02% and 65.5% at the Police Hospital, Addis Ababa [45], and in a survey of 10 
Korean hospitals [5] respectively; lower though than seen in our study. This again may be due 
to the inclusion of the ceftriaxone package insert in our study coupled with previous activities. 
Having said this, further analysis of our study showed that if the appropriateness of prescribed 
ceftriaxone was assessed against only the indication, dose, daily dose regimen and duration of 
therapy, as seen in other studies reported in Africa, the appropriateness of use would have been 
96.7% instead of 93%. This suggests that the number of variables used to determine 
appropriateness of a prescribed medicine will appreciably influence guideline adherence rates. 
 
Unstated suspected bacterial co-infection on patient cards could be an underlying reason why 
ceftriaxone was being prescribed in some the cases, which were inappropriate by our criteria. 
This will be addressed in future studies.  
 
Interestingly, most of the indications for which ceftriaxone was being prescribed in our study 
were not in the national STGs; however, justification was based on the ceftriaxone package 
insert. The main reason for this current situation could be that the aim of national STGs is to 
ensure the use of affordable and effective medicines, in line with the concept of an essential 
medicine list, and primarily aimed at ambulatory care. The hospital situation can be different. 
 
Common erroneous drug dosage regimens, which include prescribing of sub-therapeutic or 
excessive doses, as well as the wrong frequency of administration, have been associated with 
antimicrobial therapy [56]. However, our study showed that all doses prescribed for infants, 
children and adults were in line with the reference sources. In addition, 84.5% of the doses 
were prescribed once daily (every 24 hours), whilst 15.5% were prescribed twice daily. 
Furthermore, 80.8 % of the doses prescribed were either 1 or 2 g, suggesting most of the 
patients in this study were over 12 years, which appears to agree with our demographic data 
which revealed that 72.5% of patients were older than 13 years (Table 1). Instances of high 
doses of 3 ± 4 g were observed, but these were rationally prescribed for the management of 
meningitis in adults. This again endorses the appropriate use of ceftriaxone that was generally 
seen in our study. 
 
Reports have shown that duration of antibiotic use correlates with resistance prevalence [46-
48].  Hence, adherence to minimum required duration of antibiotics therapy can mitigate 
against the development of resistance by microorganisms. In our study, ceftriaxone was 
prescribed once daily for either 1 or 2 days in 86.5 % of the cases, whilst prescriptions for 3 ± 
5 days constituted 13.5%. Overall, 87.6% of prescribed ceftriaxone injections were given in 
outpatients for short courses. As a result, it was not surprising that 74.1% of cases required 
supportive or additional antibiotics to complete patient treatment. The relatively high cost of 
ceftriaxone to patients and the healthcare system, coupled with most of the cases seen on an 
outpatient basis, could be the reason underpinning the need to continue initial ceftriaxone 
injections with oral antibiotics in most patients. However, if these outpatients fail to comply 
with the supportive or additional oral antibiotics after their initial dose of ceftriaxone, this could 
contribute antimicrobial resistance to ceftriaxone unless addressed. Common antibiotics that 
were often prescribed with ceftriaxone included ciprofloxacin, penicillin, metronidazole, 
doxycycline, cefuroxime, amoxicillin and ciprofloxacin-tinidazole. This will be explored 
further in future research projects to improve antibiotic prescribing as part of stewardship 
programmes.  
 
Establishing criteria for evaluating medicine use based on evidence based sources, recognized 
LQWHUQDWLRQDODQGORFDOH[SHUWV¶UHPDLQVWKHPRVWLPSRUWDQWSURFedure in DUE [39]. In addition, 
setting a threshold of 90 ± 95% for each criteria, against which the actual threshold is 
determined, is seen as appropriate to assess rational drug use to optimize future use [39]. 
However, most DUE studies often end with determination of percentages of appropriateness 
and inappropriateness but fail to fulfil the WHO-MSH requirement of determining actual 
thresholds against pre-set thresholds. In this study, the overall actual threshold for all the drug 
use indicators was 93.0% as against an expected threshold of 97.9%.  
 
Overall, there appeared to be a high level of rational use of ceftriaxone at the Police hospital in 
Ghana, based on the percentage appropriateness of all the criteria variables, which ranged from 
85.7% to 100% (Table 3). Whilst the high overall target (threshold) of 97.9% was not attained, 
the overall rate of rational use of ceftriaxone injection for the individual indicators was high.  
However, there was some inappropriate prescribing.  The most common was the duration of 
therapy, followed closely by inappropriate indications. This was similar to studies in Ethiopia 
[42,43,45] and Thailand [49]. 74.1% (186) of the cases in which ceftriaxone was prescribed 
also required additional or supportive antibiotics to complete drug therapy. This means 
prescribers in the future should ensure that adequate and appropriate complementary antibiotics 
are prescribed together with ceftriaxone to complete drug therapy. This will be a target for the 
future with threshold rates enhanced through targeted educational activities. 
 
The possibility of incompatibility of ceftriaxone with calcium containing solutions such as 
+DUWPDQQ¶V VROXWLRQ RU 5LQJHU¶V VROXWLRQ, amscarine, vancomycin, fluconazole and 
aminoglycosides is cautioned in the package insert.  Co-prescribing with 5LQJHU¶VODFWDWHwas 
seen in 12.4% of prescriptions, lower though than rates of 40.9% to 44.5% in Ethiopia [43]. 
The actual threshold obtained for the absence of possible drug-drug interactions was 87.7% 
compared to the minimum expected pre-set threshold of 95%. Consequently, there is a need 
for prescribers to continue to minimize such co-prescriptions and use alternative maintenance 
fluids where pertinent. However, no such adverse reports (drug incompatibility effects) were 
reported within the study period. With respect to contraindications to ceftriaxone prescribing, 
no such instances were observed in this study; consequently, the actual and the pre-set 
thresholds were the same at 100%, which is encouraging. 
 
We accept that there are major limitations in our study. These include the fact that the study 
was only carried out in only one centre in Ghana and for only six months reducing the potential 
to record any seasonality. We also accept that we did not assess how diagnoses stated on patient 
cards were made, just the diagnosis. This may well have resulted in higher adherence rates in 
view of the broad categories of infection within the package insert. We also did not capture 
patients who should have been prescribed ceftriaxone but were prescribed other antibiotics, 
neither did we capture when ceftriaxone was started, which is important to optimise its use in 
sepsis and pneumonia. We also did not segment patients into in- and out-patients given the 
relatively small number of in-patients given ceftriaxone. However, in view of the nature of the 
hospital, and its referral nature, as well as the number of prescriptions analysed, we believe our 
findings are valid and provide direction for the future. We will though be undertaking future 
studies among hospitals in Ghana to further assess the appropriateness of ceftriaxone injections 
using more rigorous criteria. This includes antibiograms as well as upgraded treatment 
guidance including timings. There will also be targeted education interventions in our hospitals 
based on this and future activities including the duration of therapy, wrong indication or 
unstated comorbid indications. The impact of these activities will be assessed to further 
improve antibiotic use among hospitals in Ghana. We also hope our findings will be of interest 
to other African countries as they seek to improve antibiotic use in their hospitals.  
 
CONCLUSION 
 
The study revealed that the appropriateness of ceftriaxone prescribed (duration and indications) 
was lower than expected. Having said this, pre-set levels were high at 95% to 100% based on 
WHO and MSH recommendations. We believe our findings can be exported to other hospitals 
in Ghana to improve their utilisation of ceftriaxone. Findings of ceftriaxone-use-related 
problems in this study also provide a rational for further targeted education of prescribers and 
other health care workers at the Ghana Police Hospital as well as other hospitals in Ghana.  
Such programs will be the subject of future research activities in this and other hospitals in 
Ghana to attain agreed pre-set levels. This will form part of future antibiotic stewardship 
programmes. 
 
 
Key Messages 
 
x Several rational drug use studies conducted in Ghana have revealed high proportions of 
antibiotics on prescriptions, appreciably above national and WHO indices per 
prescription. 
x Ceftriaxone injection is among the most frequently prescribed antibiotic in Ghana due 
to its known efficacy and safety profile, coupled with its once or twice -daily ease of 
administration.  
x The Pharmacy Department, of the National Police Hospital which is also a referral 
hospital during national disaster, conducted a cross-sectional study in its facility on the 
evaluation of ceftriaxone injection from January to June 2015. 
x The observed threshold of appropriateness of ceftriaxone prescribed was 93.0 % as 
against expected (pre-set) threshold of 97.9 %. Inappropriate indication and duration of 
prescribing were identified as most common areas with prescribing errors. 
x Though findings suggest high adherence to STGs and ceftriaxone package insert 
recommendations. However, targeted education of prescribers could further improve 
its prescribing at the facility especially in outpatients 
x The findings of this study provides baseline data for similar studies among secondary 
and tertiary health facilities in Ghana in addition to this hospital including the potential 
instigation of antibiotic stewardship programmes 
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